Shares of Oncolytics Biotech, Inc. (NASDAQ:ONCY) have earned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.
Brokers have set a 12 month consensus target price of $19.00 for the company, according to Zacks. Zacks has also assigned Oncolytics Biotech an industry rank of 65 out of 256 based on the ratings given to its competitors.
Separately, Zacks Investment Research upgraded shares of Oncolytics Biotech from a “hold” rating to a “buy” rating and set a $2.00 target price for the company in a research note on Friday, May 17th.
An institutional investor recently bought a new position in Oncolytics Biotech stock. Scotia Capital Inc. acquired a new position in shares of Oncolytics Biotech, Inc. (NASDAQ:ONCY) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 44,489 shares of the company’s stock, valued at approximately $80,000. Scotia Capital Inc. owned about 0.26% of Oncolytics Biotech at the end of the most recent quarter. 0.97% of the stock is owned by institutional investors.
NASDAQ ONCY traded down $0.05 during trading hours on Wednesday, hitting $1.68. The company’s stock had a trading volume of 1,801 shares, compared to its average volume of 58,842. The stock has a fifty day moving average of $1.76. Oncolytics Biotech has a twelve month low of $1.60 and a twelve month high of $6.04. The firm has a market cap of $34.91 million, a price-to-earnings ratio of -2.11 and a beta of 2.15. The company has a quick ratio of 3.39, a current ratio of 3.39 and a debt-to-equity ratio of 0.07.
Oncolytics Biotech (NASDAQ:ONCY) last issued its quarterly earnings data on Thursday, May 2nd. The company reported ($0.21) EPS for the quarter. As a group, sell-side analysts anticipate that Oncolytics Biotech will post -0.98 EPS for the current year.
About Oncolytics Biotech
Oncolytics Biotech Inc, a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses.
Recommended Story: What does EPS mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.